{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:35:20Z","timestamp":1793914520577,"version":"4.8.0"},"reference-count":229,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.<\/jats:p>","DOI":"10.1093\/cid\/ciaa241","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T07:24:36Z","timestamp":1583479476000},"page":"e1-e36","source":"Crossref","is-referenced-by-count":821,"title":["Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline"],"prefix":"10.1093","volume":"71","author":[{"given":"Charles L","family":"Daley","sequence":"first","affiliation":[{"name":"Department of Medicine, National Jewish Health, Denver, Colorado, USA"},{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M","family":"Iaccarino","sequence":"additional","affiliation":[{"name":"Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[{"name":"Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany"},{"name":"German Center for Infection Research (DZIF), Clinical Tuberculosis Unit, Borstel, Germany"},{"name":"Respiratory Medicine & International Health, University of L\u00fcbeck, L\u00fcbeck, Germany"},{"name":"Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Cambau","sequence":"additional","affiliation":[{"name":"National Reference Center for Mycobacteria and Antimycobacterial Resistance, APHP -H\u00f4pital Lariboisi\u00e8re, Bacteriology; Inserm, University Paris Diderot, IAME UMR1137, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Richard J","family":"Wallace","sequence":"additional","affiliation":[{"name":"Mycobacteria\/Nocardia Laboratory, Department of Microbiology, The University of Texas Health Science Center, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Andrejak","sequence":"additional","affiliation":[{"name":"Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, France"},{"name":"EA 4294, AGIR, Jules Verne Picardy University, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik C","family":"B\u00f6ttger","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology, National Reference Center for Mycobacteria, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Brozek","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology & Biostatistics, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Griffith","sequence":"additional","affiliation":[{"name":"Pulmonary Infectious Disease Section, University of Texas Health Science Center, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-9635","authenticated-orcid":false,"given":"Lorenzo","family":"Guglielmetti","sequence":"additional","affiliation":[{"name":"National Reference Center for Mycobacteria and Antimycobacterial Resistance, APHP -H\u00f4pital Lariboisi\u00e8re, Bacteriology; Inserm, University Paris Diderot, IAME UMR1137, Paris, France"},{"name":"Team E13 (Bact\u00e9riologie), Centre d\u2019Immunologie et des Maladies Infectieuses, Sorbonne Universit\u00e9, Universit\u00e9 Pierre et Marie Curie, Universit\u00e9 Paris 06, Centre de Recherche 7, INSERM, IAME UMR1137, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen A","family":"Huitt","sequence":"additional","affiliation":[{"name":"Department of Medicine, National Jewish Health, Denver, Colorado, USA"},{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shandra L","family":"Knight","sequence":"additional","affiliation":[{"name":"Library and Knowledge Services, National Jewish Health, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Leitman","sequence":"additional","affiliation":[{"name":"NTM Info & Research, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore K","family":"Marras","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto and University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth N","family":"Olivier","sequence":"additional","affiliation":[{"name":"Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Santin","sequence":"additional","affiliation":[{"name":"Service of Infectious Diseases, Bellvitge University Hospital-IDIBELL, University of Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E","family":"Stout","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tortoli","sequence":"additional","affiliation":[{"name":"Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[{"name":"Radboud Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Wagner","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases, Schools of Public Health and Medicine, Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"2020121822291841000_CIT0001","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/rccm.200602-197ST","article-title":"An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations","volume":"174","author":"Sch\u00fcnemann","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0002","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2020121822291841000_CIT0003","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation\u2019s direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2020121822291841000_CIT0004","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0005","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1378\/chest.99.3.667","article-title":"Diagnosis of disease caused by Mycobacterium avium complex","volume":"99","author":"Tsukamura","year":"1991","journal-title":"Chest"},{"key":"2020121822291841000_CIT0006","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.diagmicrobio.2012.09.021","article-title":"Clinical significance of a single isolation of pathogenic nontuberculous mycobacteria from sputum specimens","volume":"75","author":"Koh","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020121822291841000_CIT0007","doi-asserted-by":"crossref","first-page":"250.e1","DOI":"10.1016\/j.cmi.2014.08.025","article-title":"Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2020121822291841000_CIT0008","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/thx.2008.110957","article-title":"Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands","volume":"64","author":"van Ingen","year":"2009","journal-title":"Thorax"},{"key":"2020121822291841000_CIT0009","doi-asserted-by":"crossref","first-page":"934","DOI":"10.5588\/ijtld.15.0633","article-title":"Microbiological criteria in non-tuberculous mycobacteria pulmonary disease: a tool for diagnosis and epidemiology","volume":"20","author":"Jankovic","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020121822291841000_CIT0010","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.meegid.2011.10.006","article-title":"Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?","volume":"12","author":"van Ingen","year":"2012","journal-title":"Infect Genet Evol"},{"key":"2020121822291841000_CIT0011","article-title":"Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype","volume":"50:1602503","author":"Koh","year":"2017","journal-title":"Eur Respir J"},{"key":"2020121822291841000_CIT0012","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/ciw724","article-title":"Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease","volume":"64","author":"Koh","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0013","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/341207","article-title":"Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis","volume":"186","author":"Wallace","year":"2002","journal-title":"J Infect Dis"},{"key":"2020121822291841000_CIT0014","volume-title":"Susceptibility testing of mycobacteria, Nocardia spp, and other aerobic actinomyces","author":"CLSI","year":"2018","edition":"3"},{"key":"2020121822291841000_CIT0015","volume-title":"Performance standards for susceptibility testing of mycobacteia, Nocardia spp, and other aerobic actinonmyces","author":"CLSI","year":"2018","edition":"1"},{"key":"2020121822291841000_CIT0016","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0017","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0018","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2020121822291841000_CIT0019","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0020","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"mikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). a prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0021","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease: a preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2020121822291841000_CIT0022","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/Azalide therapy for nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"key":"2020121822291841000_CIT0023","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","article-title":"Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"191","author":"Jeong","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0024","first-page":"31","article-title":"Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii","volume":"112","author":"Harris","year":"1975","journal-title":"Am Rev Respir Dis"},{"key":"2020121822291841000_CIT0025","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1378\/chest.129.3.771","article-title":"Pulmonary Mycobacterium kansasii infection in Israel, 1999\u20132004: clinical features, drug susceptibility, and outcome","volume":"129","author":"Shitrit","year":"2006","journal-title":"Chest"},{"key":"2020121822291841000_CIT0026","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1086\/378742","article-title":"Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study","volume":"37","author":"Griffith","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0027","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0962-8479(95)90550-2","article-title":"Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months\u2019 chemotherapy","volume":"76","author":"Sauret","year":"1995","journal-title":"Tuber Lung Dis"},{"key":"2020121822291841000_CIT0028","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1183\/09031936.00024008","article-title":"Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease","volume":"33","author":"Santin","year":"2009","journal-title":"Eur Respir J"},{"key":"2020121822291841000_CIT0029","first-page":"1048","article-title":"Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii","volume":"128","author":"Ahn","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"2020121822291841000_CIT0030","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/clinids\/3.5.1035","article-title":"Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin","volume":"3","author":"Pezzia","year":"1981","journal-title":"Rev Infect Dis"},{"key":"2020121822291841000_CIT0031","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/clinids\/3.5.1028","article-title":"Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs","volume":"3","author":"Ahn","year":"1981","journal-title":"Rev Infect Dis"},{"key":"2020121822291841000_CIT0032","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijantimicag.2013.03.010","article-title":"Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance","volume":"42","author":"van Ingen","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2020121822291841000_CIT0033","first-page":"A3733","article-title":"Camomy Trial: a prospective randomized clinical trial to compare six-months sputum conversion rate with a clarithromycin or moxifloxacin containing regimen in patients with a M. xenopi pulmonary infection: intermediate analysis","volume":"193","author":"Andrejak","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0034","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3201\/eid2303.161927","article-title":"Pulmonary nontuberculous mycobacteria-associated deaths, Ontario, Canada, 2001\u20132013","volume":"23","author":"Marras","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2020121822291841000_CIT0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/thx.2008.096842","article-title":"Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France","volume":"64","author":"Andr\u00e9jak","year":"2009","journal-title":"Thorax"},{"key":"2020121822291841000_CIT0036","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/rmed.2002.1444","article-title":"Pulmonary disease caused by Mycobacterium xenopi in -negative patients: five year follow-up of patients receiving standardised treatment","volume":"97","author":"Jenkins","year":"2003","journal-title":"Respir Med"},{"key":"2020121822291841000_CIT0037","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/thx.39.5.376","article-title":"Pulmonary infection with Mycobacterium xenopi: review of treatment and response","volume":"39","author":"Banks","year":"1984","journal-title":"Thorax"},{"key":"2020121822291841000_CIT0038","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1164\/rccm.201003-0395OC","article-title":"Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus","volume":"183","author":"Koh","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0039","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/rccm.200905-0704OC","article-title":"Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients","volume":"180","author":"Jeon","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0040","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1128\/AAC.00861-10","article-title":"Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing","volume":"55","author":"Bastian","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0041","article-title":"Selection of resistance to clarithromycin in Mycobacterium abscessus subspecies","volume":"61:e00943-16","author":"Mougari","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0042","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/jac\/dkw130","article-title":"Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar","volume":"71","author":"Mougari","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020121822291841000_CIT0043","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.athoracsur.2008.02.041","article-title":"Anatomic lung resection for nontuberculous mycobacterial disease","volume":"85","author":"Mitchell","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"2020121822291841000_CIT0044","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3201\/eid1911.130737","article-title":"Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998\u20132010","volume":"19","author":"Marras","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"2020121822291841000_CIT0045","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1164\/rccm.201111-2016OC","article-title":"Prevalence of nontuberculous mycobacterial lung disease in US Medicare beneficiaries","volume":"185","author":"Adjemian","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0046","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"key":"2020121822291841000_CIT0047","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1513\/AnnalsATS.201412-559OC","article-title":"Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012","volume":"12","author":"Henkle","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2020121822291841000_CIT0048","first-page":"1176","article-title":"The changing pattern of clinical Mycobacterium avium isolation in the Netherlands","volume":"14","author":"van Ingen","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020121822291841000_CIT0049","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1099\/ijsem.0.003026","article-title":"A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review","volume":"68","author":"van Ingen","year":"2018","journal-title":"Int J Syst Evol Microbiol"},{"key":"2020121822291841000_CIT0050","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2020121822291841000_CIT0051","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s10156-003-0267-1","article-title":"Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by Mycobacterium avium-intracellulare complex (MAC) infection","volume":"9","author":"Sugihara","year":"2003","journal-title":"J Infect Chemother"},{"key":"2020121822291841000_CIT0052","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1164\/ajrccm.155.6.9196113","article-title":"Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease","volume":"155","author":"Tanaka","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0053","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1378\/chest.115.4.1033","article-title":"Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations","volume":"115","author":"Huang","year":"1999","journal-title":"Chest"},{"key":"2020121822291841000_CIT0054","doi-asserted-by":"crossref","first-page":"728","DOI":"10.11150\/kansenshogakuzasshi1970.73.728","article-title":"Usefulness of bronchoscopy for the diagnosis of atypical pulmonary mycobacteriosis","volume":"73","author":"Watanuki","year":"1999","journal-title":"Kansenshogaku Zasshi"},{"key":"2020121822291841000_CIT0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2739\/kurumemedj.48.15","article-title":"The significance of bronchoscopy for the diagnosis of Mycobacterium avium complex (MAC) pulmonary disease","volume":"48","author":"Ikedo","year":"2001","journal-title":"Kurume Med J"},{"key":"2020121822291841000_CIT0056","first-page":"1572","article-title":"Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture","volume":"13","author":"Peres","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020121822291841000_CIT0057","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/JCM.42.5.2321-2325.2004","article-title":"Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria","volume":"42","author":"Cruciani","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0058","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1099\/00222615-47-9-821","article-title":"Clinical evaluation of the Mycobacteria Growth Indicator Tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of Mycobacterium species","volume":"47","author":"Chew","year":"1998","journal-title":"J Med Microbiol"},{"key":"2020121822291841000_CIT0059","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s100960050492","article-title":"Comparison of the automated nonradiometric Bactec MGIT 960 system with L\u00f6wenstein-Jensen, Coletsos, and Middlebrook 7H11 solid media for recovery of mycobacteria","volume":"19","author":"Idigoras","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020121822291841000_CIT0060","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4014\/jmb.0901.0059","article-title":"Comparative evaluation of three culture methods for the isolation of mycobacteria from clinical samples","volume":"19","author":"Sorlozano","year":"2009","journal-title":"J Microbiol Biotechnol"},{"key":"2020121822291841000_CIT0061","first-page":"454","article-title":"Rapid and improved recovery rate of Mycobacterium tuberculosis in mycobacteria growth indicator tube combined with solid L\u00f6wenstein Jensen medium","volume":"1","author":"Rivera","year":"1997","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020121822291841000_CIT0062","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1128\/JCM.38.1.398-401.2000","article-title":"Evaluation of the BACTEC MGIT 960 and the MB\/BacT systems for recovery of mycobacteria from clinical specimens and for species identification by DNA AccuProbe","volume":"38","author":"Alcaide","year":"2000","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0063","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1309\/65KN-2M7E-7MNN-X0TA","article-title":"Comparison of the automated mycobacteria growth indicator tube system (BACTEC 960\/MGIT) with L\u00f6wenstein-Jensen medium for recovery of mycobacteria from clinical specimens","volume":"118","author":"Lu","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"2020121822291841000_CIT0064","first-page":"569","article-title":"Comparative evaluation of the BACTEC MGIT 960 system with solid medium for isolation of mycobacteria","volume":"7","author":"Lee","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020121822291841000_CIT0065","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1128\/JCM.00829-06","article-title":"Use of the BACTEC mycobacteria growth indicator tube 960 automated system for recovery of mycobacteria from 9,558 extrapulmonary specimens, including urine samples","volume":"44","author":"Hillemann","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0066","volume-title":"Laboratory detection and identification of mycobacteria","author":"CLSI","year":"2018","edition":"2"},{"key":"2020121822291841000_CIT0067","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1128\/JCM.00513-11","article-title":"Evaluation of BacT\/Alert 3D automated unit for detection of nontuberculous mycobacteria requiring incubation at 30 degrees C for optimal growth","volume":"49","author":"Alfa","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0068","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1128\/JCM.00851-10","article-title":"Detection and identification of Mycobacterium spp. in clinical specimens by combining the Roche Cobas amplicor Mycobacterium tuberculosis assay with Mycobacterium genus detection and nucleic acid sequencing","volume":"48","author":"Peter-Getzlaff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0069","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ebiom.2016.06.016","article-title":"Diagnostic molecular mycobacteriology in regions with low tuberculosis endemicity: combining real-time PCR assays for detection of multiple mycobacterial pathogens with line probe assays for identification of resistance mutations","volume":"9","author":"Deggim-Messmer","year":"2016","journal-title":"EBioMedicine"},{"key":"2020121822291841000_CIT0070","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/j.1469-0691.2010.03123.x","article-title":"Re-analysis of 178 previously unidentifiable Mycobacterium isolates in the Netherlands in 1999\u20132007","volume":"16","author":"van Ingen","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2020121822291841000_CIT0071","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1128\/JCM.01536-09","article-title":"Commercial DNA probes for mycobacteria incorrectly identify a number of less frequently encountered species","volume":"48","author":"Tortoli","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0072","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1128\/JCM.42.7.3000-3011.2004","article-title":"Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources","volume":"42","author":"McNabb","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0073","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1128\/JCM.41.12.5699-5708.2003","article-title":"rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria","volume":"41","author":"Ad\u00e9kambi","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0074","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/JCM.00233-14","article-title":"Utility of rpoB gene sequencing for identification of nontuberculous mycobacteria in the Netherlands","volume":"52","author":"de Zwaan","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0075","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/JCM.36.1.139-147.1998","article-title":"Differentiation of phylogenetically related slowly growing mycobacteria based on 16S-23S rRNA gene internal transcribed spacer sequences","volume":"36","author":"Roth","year":"1998","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0076","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1099\/jmm.0.045070-0","article-title":"Characterization of a novel variant of Mycobacterium chimaera","volume":"61","author":"van Ingen","year":"2012","journal-title":"J Med Microbiol"},{"key":"2020121822291841000_CIT0077","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/JCM.01274-10","article-title":"Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains","volume":"49","author":"Macheras","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0078","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1128\/JCM.01688-08","article-title":"Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii","volume":"47","author":"Zelazny","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0079","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cmi.2017.11.012","article-title":"How to: identify non-tuberculous Mycobacterium species using MALDI-TOF mass spectrometry","volume":"24","author":"Alcaide","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2020121822291841000_CIT0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1309\/AJCPBPUBUDEW2OAG","article-title":"Comparison of MALDI-TOF MS with HPLC and nucleic acid sequencing for the identification of Mycobacterium species in cultures using solid medium and broth","volume":"141","author":"Buchan","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"2020121822291841000_CIT0081","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1128\/JCM.00006-17","article-title":"Comparison of Saramis 4.12 and IVD 3.0 Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of mycobacteria from solid and liquid culture media","volume":"55","author":"Leyer","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0082","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1128\/JCM.00304-16","article-title":"Matrix-assisted laser desorption ionization-time of flight mass spectrometry fails to identify nontuberculous mycobacteria from primary cultures of respiratory samples","volume":"54","author":"van Eck","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0083","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1164\/ajrccm.153.6.8665032","article-title":"Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients","volume":"153","author":"Wallace","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0084","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/ajrccm.160.3.9811086","article-title":"Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease","volume":"160","author":"Tanaka","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0085","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/174.2.354","article-title":"Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population","volume":"174","author":"Meier","year":"1996","journal-title":"J Infect Dis"},{"key":"2020121822291841000_CIT0086","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1128\/AAC.38.2.381","article-title":"Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare","volume":"38","author":"Meier","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0087","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates","volume":"51","author":"Brown-Elliott","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0088","volume-title":"Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard-second edition. CLSI document M24-A2","author":"(CLSI). CaLSI","year":"2011"},{"key":"2020121822291841000_CIT0089","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciq237","article-title":"Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease","volume":"52","author":"Jarand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0090","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1684-1182(10)60063-1","article-title":"Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing","volume":"43","author":"Huang","year":"2010","journal-title":"J Microbiol Immunol Infect"},{"key":"2020121822291841000_CIT0091","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/AAC.01505-12","article-title":"In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease","volume":"56","author":"van Ingen","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0092","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1128\/AAC.02615-15","article-title":"Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0093","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0094","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1128\/AAC.40.7.1676","article-title":"Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus","volume":"40","author":"Wallace","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0095","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5588\/ijtld.11.0148","article-title":"Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease","volume":"16","author":"Ito","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020121822291841000_CIT0096","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/resp.12287","article-title":"Mycobacterium avium complex infection in non-cystic fibrosis bronchiectasis","volume":"19","author":"Zoumot","year":"2014","journal-title":"Respirology"},{"key":"2020121822291841000_CIT0097","article-title":"Natural history of Mycobacterium avium com\u2002plex lung disease in untreated patients with stable course","volume":"49:1600537","author":"Hwang","year":"2017","journal-title":"Eur Respir J"},{"key":"2020121822291841000_CIT0098","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/thx.36.5.326","article-title":"Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex","volume":"36","author":"Hunter","year":"1981","journal-title":"Thorax"},{"key":"2020121822291841000_CIT0099","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1513\/AnnalsATS.201303-062OC","article-title":"Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans","volume":"10","author":"Lee","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"2020121822291841000_CIT0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rmed.2014.10.013","article-title":"Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study","volume":"109","author":"Gommans","year":"2015","journal-title":"Respir Med"},{"key":"2020121822291841000_CIT0101","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jinf.2007.01.008","article-title":"Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients","volume":"55","author":"Andr\u00e9jak","year":"2007","journal-title":"J Infect"},{"key":"2020121822291841000_CIT0102","doi-asserted-by":"crossref","first-page":"e008058","DOI":"10.1136\/bmjopen-2015-008058","article-title":"Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"5","author":"Gochi","year":"2015","journal-title":"BMJ Open"},{"key":"2020121822291841000_CIT0103","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","article-title":"Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems","volume":"182","author":"Prevots","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0104","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1164\/rccm.201107-1203OC","article-title":"Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease","volume":"185","author":"Hayashi","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rmed.2016.10.001","article-title":"Factors which influence treatment initiation for pulmonary non-tuberculous Mycobacterium infection in HIV negative patients; a multicentre observational study","volume":"120","author":"Rawson","year":"2016","journal-title":"Respir Med"},{"key":"2020121822291841000_CIT0106","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.rmed.2011.08.004","article-title":"Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease","volume":"105","author":"Mehta","year":"2011","journal-title":"Respir Med"},{"key":"2020121822291841000_CIT0107","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s11136-014-0727-3","article-title":"Factors associated with quality of life measured by EQ-5D in patients with nontuberculous mycobacterial pulmonary disease","volume":"23","author":"Hong","year":"2014","journal-title":"Qual Life Res"},{"key":"2020121822291841000_CIT0108","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1513\/AnnalsATS.201508-529OC","article-title":"Improvement in quality of life after therapy for Mycobacterium abscessus group lung infection: a prospective cohort study","volume":"13","author":"Czaja","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2020121822291841000_CIT0109","doi-asserted-by":"crossref","first-page":"660","DOI":"10.5588\/ijtld.11.0534","article-title":"Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease","volume":"16","author":"Kitada","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020121822291841000_CIT0110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria","volume":"25","author":"Brown-Elliott","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2020121822291841000_CIT0111","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","article-title":"Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria","volume":"15","author":"van Ingen","year":"2012","journal-title":"Drug Resist Updat"},{"key":"2020121822291841000_CIT0112","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10156-006-0457-8","article-title":"Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates","volume":"12","author":"Kobashi","year":"2006","journal-title":"J Infect Chemother"},{"key":"2020121822291841000_CIT0113","doi-asserted-by":"crossref","first-page":"905","DOI":"10.7326\/0003-4819-121-12-199412150-00001","article-title":"Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team","volume":"121","author":"Chaisson","year":"1994","journal-title":"Ann Intern Med"},{"key":"2020121822291841000_CIT0114","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/clinids\/18.5.736","article-title":"Rifampin-resistant Mycobacterium kansasii","volume":"18","author":"Wallace","year":"1994","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0115","first-page":"10","article-title":"Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii","volume":"135","author":"Ahn","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"2020121822291841000_CIT0116","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/infdis\/173.3.677","article-title":"Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans?","volume":"173","author":"Sison","year":"1996","journal-title":"J Infect Dis"},{"key":"2020121822291841000_CIT0117","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1164\/ajrccm.149.5.8173775","article-title":"Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease","volume":"149","author":"Wallace","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0118","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10156-011-0351-x","article-title":"Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period","volume":"18","author":"Kobashi","year":"2012","journal-title":"J Infect Chemother"},{"key":"2020121822291841000_CIT0119","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/thorax.56.3.167","article-title":"First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol","volume":"56","author":"Research Committee of the British Thoracic S","year":"2001","journal-title":"Thorax"},{"key":"2020121822291841000_CIT0120","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1086\/515328","article-title":"A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae","volume":"177","author":"Prammananan","year":"1998","journal-title":"J Infect Dis"},{"key":"2020121822291841000_CIT0121","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi","year":"2007","journal-title":"Respir Med"},{"key":"2020121822291841000_CIT0122","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/thx.38.5.373","article-title":"Clinical review of pulmonary disease caused by Mycobacterium xenopi","volume":"38","author":"Smith","year":"1983","journal-title":"Thorax"},{"key":"2020121822291841000_CIT0123","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3201\/eid1403.061393","article-title":"Mycobacterium xenopi clinical relevance and determinants, the Netherlands","volume":"14","author":"van Ingen","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"2020121822291841000_CIT0124","article-title":"Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium massiliense lung disease","volume":"61:e02189-16","author":"Choi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0125","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/jac\/dks279","article-title":"Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41)","volume":"67","author":"Maurer","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020121822291841000_CIT0126","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/ajrccm\/144.3_Pt_1.564","article-title":"Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: a controlled clinical trial","volume":"144","author":"Dautzenberg","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"2020121822291841000_CIT0127","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1056\/NEJM199608083350603","article-title":"A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome","volume":"335","author":"Pierce","year":"1996","journal-title":"N Engl J Med"},{"key":"2020121822291841000_CIT0128","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1056\/NEJM199608083350604","article-title":"Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group","volume":"335","author":"Havlir","year":"1996","journal-title":"N Engl J Med"},{"key":"2020121822291841000_CIT0129","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199608083350602","article-title":"A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group","volume":"335","author":"Shafran","year":"1996","journal-title":"N Engl J Med"},{"key":"2020121822291841000_CIT0130","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/378807","article-title":"A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome","volume":"37","author":"Benson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0131","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/thx.2007.087999","article-title":"Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy","volume":"63","author":"Jenkins","year":"2008","journal-title":"Thorax"},{"key":"2020121822291841000_CIT0132","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10156-011-0303-5","article-title":"The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease","volume":"18","author":"Fujita","year":"2012","journal-title":"J Infect Chemother"},{"key":"2020121822291841000_CIT0133","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkx311","article-title":"Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease","volume":"72","author":"Pasipanodya","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020121822291841000_CIT0134","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"2020121822291841000_CIT0135","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"2020121822291841000_CIT0136","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jiac.2017.01.007","article-title":"The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: a nationwide post-marketing study","volume":"23","author":"Kadota","year":"2017","journal-title":"J Infect Chemother"},{"key":"2020121822291841000_CIT0137","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1378\/chest.126.2.566","article-title":"Mycobacterium avium complex pulmonary disease in patients without HIV infection","volume":"126","author":"Field","year":"2004","journal-title":"Chest"},{"key":"2020121822291841000_CIT0138","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/clinids\/23.5.983","article-title":"Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus","volume":"23","author":"Griffith","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0139","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1086\/313644","article-title":"Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex","volume":"30","author":"Griffith","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0140","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/320512","article-title":"Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease","volume":"32","author":"Griffith","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0141","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.124.4.1482","article-title":"Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine","volume":"124","author":"Field","year":"2003","journal-title":"Chest"},{"key":"2020121822291841000_CIT0142","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0924-8579(01)00397-1","article-title":"Comparative safety of the different macrolides","volume":"18","author":"Rubinstein","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"2020121822291841000_CIT0143","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/clinids\/21.3.594","article-title":"Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease","volume":"21","author":"Griffith","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0144","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/14656560802694564","article-title":"Tuberculosis pharmacotherapy: strategies to optimize patient care","volume":"10","author":"Mitnick","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"2020121822291841000_CIT0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment","volume":"186","author":"van Ingen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0146","first-page":"400","article-title":"Interaction between midazolam and clarithromycin: comparison with azithromycin","volume":"34","author":"Yeates","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2020121822291841000_CIT0147","doi-asserted-by":"crossref","first-page":"f1235","DOI":"10.1136\/bmj.f1235","article-title":"Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies","volume":"346","author":"Schembri","year":"2013","journal-title":"BMJ"},{"key":"2020121822291841000_CIT0148","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000128994","article-title":"Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease","volume":"111","author":"Gluud","year":"2008","journal-title":"Cardiology"},{"key":"2020121822291841000_CIT0149","first-page":"CD011825","article-title":"Adverse events in people taking macrolide antibiotics versus placebo for any indication","volume":"1","author":"Hansen","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2020121822291841000_CIT0150","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/clinids\/24.5.958","article-title":"Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease","volume":"24","author":"Brown","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0151","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0732-8893(93)90112-K","article-title":"Drug intolerance to high-dose clarithromycin among elderly patients","volume":"16","author":"Wallace","year":"1993","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020121822291841000_CIT0152","first-page":"S1","article-title":"Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997","volume":"156","author":"Medical Section of the American Lung Association","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0153","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.rmed.2017.08.031","article-title":"Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort","volume":"131","author":"Zweijpfenning","year":"2017","journal-title":"Respir Med"},{"key":"2020121822291841000_CIT0154","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2466-7-2","article-title":"Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series","volume":"7","author":"Davis","year":"2007","journal-title":"BMC Pulm Med"},{"key":"2020121822291841000_CIT0156","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s10096-011-1516-3","article-title":"Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis","volume":"31","author":"Safdar","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020121822291841000_CIT0157","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2020121822291841000_CIT0158","doi-asserted-by":"crossref","first-page":"e00011","DOI":"10.1128\/AAC.00011-18","article-title":"Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease","volume":"62","author":"Jhun","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0159","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12879-017-2665-5","article-title":"The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases","volume":"17","author":"Yagi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2020121822291841000_CIT0160","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1513\/AnnalsATS.201311-399ED","article-title":"Treatment of pulmonary nontuberculous mycobacterial infections: many questions remain","volume":"11","author":"Daley","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2020121822291841000_CIT0161","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/514748","article-title":"A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex","volume":"28","author":"Gordin","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0162","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/0003-4819-76-3-112-6-407","article-title":"A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen","volume":"112","author":"Cohn","year":"1990","journal-title":"Ann Intern Med"},{"key":"2020121822291841000_CIT0163","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/rccm.200509-1531OC","article-title":"Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease","volume":"173","author":"Lam","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0164","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1086\/515597","article-title":"Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients","volume":"178","author":"Griffith","year":"1998","journal-title":"J Infect Dis"},{"key":"2020121822291841000_CIT0165","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.200407-863OC","article-title":"Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease","volume":"172","author":"Griffith","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0166","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0167","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1128\/AAC.00648-15","article-title":"Response to switch from intermittent therapy to daily therapy for refractory nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"59","author":"Koh","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0168","doi-asserted-by":"crossref","first-page":"e01787","DOI":"10.1128\/AAC.01812-17","article-title":"Intermittent antibiotic therapy for recurrent nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"62","author":"Jhun","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0169","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1164\/rccm.201503-0444OC","article-title":"Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease","volume":"192","author":"Griffith","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0170","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51:1800170","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"key":"2020121822291841000_CIT0171","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ajcp\/23.4.363","article-title":"Human infection with atypical acid-fast organisms; report of two cases with pathologic findings","volume":"23","author":"Buhler","year":"1953","journal-title":"Am J Clin Pathol"},{"key":"2020121822291841000_CIT0172","article-title":"Pulmonary disease due to atypical mycobacteria; current concepts","volume-title":"Transactions 19th Conference on Chemotherapy of Tuberculosis","author":"Jenkins","year":"1960"},{"key":"2020121822291841000_CIT0173","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/thx.49.5.442","article-title":"Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol","volume":"49","author":"Research Committee, British Thoracic Society.","year":"1994","journal-title":"Thorax"},{"key":"2020121822291841000_CIT0174","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1128\/AAC.48.12.4562-4565.2004","article-title":"Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii","volume":"48","author":"Alcaide","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0175","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/jac\/dki111","article-title":"In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii","volume":"55","author":"Guna","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020121822291841000_CIT0176","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.36.9.1987","article-title":"Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system","volume":"36","author":"Brown","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0177","article-title":"Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium kansasii","volume":"62:e01788-17","author":"Bakula","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0178","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccm.2014.10.005","article-title":"Treatment of slowly growing mycobacteria","volume":"36","author":"Philley","year":"2015","journal-title":"Clin Chest Med"},{"key":"2020121822291841000_CIT0179","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1378\/chest.93.3.550","article-title":"Nontuberculous mycobacterial lung disease: substantiation of a less aggressive approach","volume":"93","author":"Hornick","year":"1988","journal-title":"Chest"},{"key":"2020121822291841000_CIT0180","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijmm.2013.04.003","article-title":"Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST","volume":"303","author":"Hombach","year":"2013","journal-title":"Int J Med Microbiol"},{"key":"2020121822291841000_CIT0181","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.04441-14","article-title":"Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease","volume":"59","author":"Srivastava","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0182","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/thx.49.5.442","article-title":"Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol","volume":"49","author":"Jenkins","year":"1994","journal-title":"Thorax"},{"key":"2020121822291841000_CIT0183","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00408-011-9321-4","article-title":"Clinical characteristics and prognosis of nontuberculous mycobacterial lung disease with different radiographic patterns","volume":"189","author":"Shu","year":"2011","journal-title":"Lung"},{"key":"2020121822291841000_CIT0184","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.chest.2017.04.166","article-title":"Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis","volume":"152","author":"Diel","year":"2017","journal-title":"Chest"},{"key":"2020121822291841000_CIT0185","first-page":"1210","article-title":"Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review","volume":"13","author":"Varadi","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020121822291841000_CIT0186","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1164\/rccm.200905-0778OC","article-title":"Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors","volume":"181","author":"Andr\u00e9jak","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0187","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1592\/phco.28.8.1076","article-title":"Concomitant use of voriconazole and rifabutin in a patient with multiple infections","volume":"28","author":"Schwiesow","year":"2008","journal-title":"Pharmacotherapy"},{"key":"2020121822291841000_CIT0188","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0041-3879(88)90077-3","article-title":"Mycobacterium xenopi infection and aspergilloma","volume":"69","author":"Johnston","year":"1988","journal-title":"Tubercle"},{"key":"2020121822291841000_CIT0189","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.carj.2013.05.006","article-title":"Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi","volume":"65","author":"Carrillo","year":"2014","journal-title":"Can Assoc Radiol J"},{"key":"2020121822291841000_CIT0190","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1093\/jac\/dkv180","article-title":"Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease","volume":"70","author":"Ferro","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020121822291841000_CIT0191","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/dks421","article-title":"Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy","volume":"68","author":"Andr\u00e9jak","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020121822291841000_CIT0192","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1128\/AAC.45.11.3229-3230.2001","article-title":"Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice","volume":"45","author":"Lounis","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0193","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jinf.2009.01.001","article-title":"Mycobacterium xenopi pulmonary disease: epidemiology and clinical features in non-immunocompromised patients","volume":"58","author":"Marusi\u0107","year":"2009","journal-title":"J Infect"},{"key":"2020121822291841000_CIT0194","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1099\/ijsem.0.001376","article-title":"Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov","volume":"66","author":"Tortoli","year":"2016","journal-title":"Int J Syst Evol Microbiol"},{"key":"2020121822291841000_CIT0195","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61:e01206-17","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0196","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1164\/ajrccm\/147.5.1271","article-title":"Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients","volume":"147","author":"Griffith","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"2020121822291841000_CIT0197","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jinf.2009.08.016","article-title":"Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients","volume":"59","author":"van Ingen","year":"2009","journal-title":"J Infect"},{"key":"2020121822291841000_CIT0198","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.rmed.2010.12.012","article-title":"Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs","volume":"105","author":"Lyu","year":"2011","journal-title":"Respir Med"},{"key":"2020121822291841000_CIT0199","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/JCM.01175-12","article-title":"Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases","volume":"50","author":"Harada","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2020121822291841000_CIT0200","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jmii.2014.08.005","article-title":"Risk factors for microbiologic failure among Taiwanese adults with Mycobacterium abscessus complex pulmonary disease","volume":"48","author":"Tung","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"2020121822291841000_CIT0201","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1378\/chest.14-1297","article-title":"The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy","volume":"147","author":"Griffith","year":"2015","journal-title":"Chest"},{"key":"2020121822291841000_CIT0202","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12879-016-1689-6","article-title":"Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series","volume":"16","author":"Namkoong","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2020121822291841000_CIT0203","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/cid\/ciw723","article-title":"Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense","volume":"64","author":"Park","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0204","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.chest.2016.05.003","article-title":"Oral macrolide therapy following short-term combination antibiotic treatment of Mycobacterium massiliense lung disease","volume":"150","author":"Koh","year":"2016","journal-title":"Chest"},{"key":"2020121822291841000_CIT0205","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/resp.12676","article-title":"Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease","volume":"21","author":"Ellender","year":"2016","journal-title":"Respirology"},{"key":"2020121822291841000_CIT0206","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcf.2014.07.004","article-title":"Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients","volume":"14","author":"Roux","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2020121822291841000_CIT0207","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.rmed.2014.09.002","article-title":"A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease","volume":"108","author":"Lyu","year":"2014","journal-title":"Respir Med"},{"key":"2020121822291841000_CIT0208","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.201111-2005OC","article-title":"Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance","volume":"186","author":"Choi","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0209","doi-asserted-by":"crossref","first-page":"e15285","DOI":"10.1097\/MD.0000000000015285","article-title":"Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2020121822291841000_CIT0210","first-page":"CD012406","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2020121822291841000_CIT0211","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2016.10.055","article-title":"Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry","volume":"151","author":"Aksamit","year":"2017","journal-title":"Chest"},{"key":"2020121822291841000_CIT0212","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3201\/eid2203.150828","article-title":"Treatment of Mycobacterium abscessus infection","volume":"22","author":"Novosad","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2020121822291841000_CIT0213","first-page":"499","article-title":"Nontuberculous mycobacterial lung disease in southern Taiwan","volume":"32","author":"Wang","year":"2009","journal-title":"Chang Gung Med J"},{"key":"2020121822291841000_CIT0214","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0003-4975(98)00401-9","article-title":"Results of operation in Mycobacterium avium-intracellulare lung disease","volume":"66","author":"Nelson","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"2020121822291841000_CIT0215","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3346\/jkms.2008.23.3.397","article-title":"Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria","volume":"23","author":"Koh","year":"2008","journal-title":"J Korean Med Sci"},{"key":"2020121822291841000_CIT0216","first-page":"671","article-title":"Lady Windermere revisited: treatment with thoracoscopic lobectomy\/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease","volume":"40","author":"Yu","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"key":"2020121822291841000_CIT0217","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12879-015-0823-1","article-title":"Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease","volume":"15","author":"Kang","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2020121822291841000_CIT0218","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0003-4975(98)00373-7","article-title":"Early pulmonary resection for localized Mycobacterium avium complex disease","volume":"66","author":"Shiraishi","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"2020121822291841000_CIT0219","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.athoracsur.2004.02.103","article-title":"Pneumonectomy for nontuberculous mycobacterial infections","volume":"78","author":"Shiraishi","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"2020121822291841000_CIT0220","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S1010-7940(01)01122-8","article-title":"Surgery for Mycobacterium avium complex lung disease in the clarithromycin era","volume":"21","author":"Shiraishi","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"2020121822291841000_CIT0221","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0003-4975(01)03245-3","article-title":"Pulmonary resection for Mycobacterium xenopi pulmonary infection","volume":"72","author":"Lang-Lazdunski","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"2020121822291841000_CIT0222","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.athoracsur.2006.01.031","article-title":"Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones","volume":"81","author":"Watanabe","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"2020121822291841000_CIT0223","first-page":"99","article-title":"Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time","volume":"14","author":"van Ingen","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020121822291841000_CIT0224","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1164\/rccm.201206-1088OC","article-title":"Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease","volume":"186","author":"Koh","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0225","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijantimicag.2013.05.007","article-title":"Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections","volume":"42","author":"Magis-Escurra","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2020121822291841000_CIT0226","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1128\/AAC.00770-16","article-title":"Peak plasma concentration of azithromycin and treatment responses in Mycobacterium avium complex lung disease","volume":"60","author":"Jeong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020121822291841000_CIT0227","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020121822291841000_CIT0228","article-title":"Advancing translational science for pulmonary NTM infections: a roadmap for research","author":"Daniel-Wayman","journal-title":"Am J Respir Crit Care Med"},{"key":"2020121822291841000_CIT0229","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1513\/AnnalsATS.201605-387WS","article-title":"Patient-centered research priorities for pulmonary nontuberculous mycobacteria (NTM) infection. An NTM Research Consortium Workshop Report","volume":"13","author":"Henkle","year":"2016","journal-title":"Ann Am Thorac Soc"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa241\/33468217\/ciaa241.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/4\/e1\/35000000\/ciaa241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/4\/e1\/35000000\/ciaa241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T17:05:46Z","timestamp":1666026346000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/4\/e1\/5867961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":229,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,7,6]]},"published-print":{"date-parts":[[2020,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa241","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,15]]},"published":{"date-parts":[[2020,7,6]]}}}